Literature DB >> 9243618

5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs.

K W Johnson1, J M Schaus, M M Durkin, J E Audia, S W Kaldor, M E Flaugh, N Adham, J M Zgombick, M L Cohen, T A Branchek, L A Phebus.   

Abstract

The serotonin (5-HT) receptor subtype mediating inhibition of neurogenic dural inflammation in guinea pigs was investigated using a series of serotonin agonists with differing affinities for the 5-HT1B, 5-HT1D and 5-HT1F receptors. When agonist potencies for inhibiting neurogenic inflammation were compared with affinities for these receptor subtypes, a significant positive correlation was seen only with the 5-HT1F receptor. The potency of agonists in inhibiting adenylate cyclase in cells transfected with human 5-HT1F receptor was also highly correlated with their potency in the animal model of migraine. In situ hybridization demonstrated 5-HT1F receptor mRNA in guinea pig trigeminal ganglion neurons. These data suggest that the 5-HT1F receptor is a rational target for migraine therapeutics.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9243618     DOI: 10.1097/00001756-199707070-00029

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  26 in total

1.  No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery.

Authors:  I Bouchelet; B Case; A Olivier; E Hamel
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

2.  The antimigraine 5-HT 1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain.

Authors:  Valérie Kayser; Bertrand Aubel; Michel Hamon; Sylvie Bourgoin
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 3.  Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.

Authors:  P Tfelt-Hansen; P De Vries; P R Saxena
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

Review 4.  5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?

Authors:  Lars Neeb; Jannis Meents; Uwe Reuter
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

Review 5.  The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine.

Authors:  Uwe Reuter; Heike Israel; Lars Neeb
Journal:  Ther Adv Neurol Disord       Date:  2015-01       Impact factor: 6.570

6.  Contractile 5-HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry.

Authors:  T Nilsson; J Longmore; D Shaw; I J Olesen; L Edvinsson
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

7.  Pharmacology.

Authors:  Hayrunnisa Bolay; Paul Durham
Journal:  Handb Clin Neurol       Date:  2010

Review 8.  Eletriptan: a review of its use in the acute treatment of migraine.

Authors:  Paul L McCormack; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 9.  Migraine and the trigeminovascular system-40 years and counting.

Authors:  Messoud Ashina; Jakob Møller Hansen; Thien Phu Do; Agustin Melo-Carrillo; Rami Burstein; Michael A Moskowitz
Journal:  Lancet Neurol       Date:  2019-05-31       Impact factor: 44.182

Review 10.  Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications.

Authors:  Carlos M Villalón; David Centurión
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-08-17       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.